Skip to NavigationSkip to content

Lilly and Incyte's atopic dermatitis drug shows promise at Phase 3

Published on 13/02/20 at 12:17pm

Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib as a treatment for moderate to severe atopic dermatitis in adult patients.

The findings showed that a clinically significant proportion of the trial’s participants taking either 1mg and 2mg doses of baricitinib achieved a change of at least 75% according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment, meeting the primary endpoint of the study.

Specifically, 19% and 43% of participants in the 1mg and 2mg dose groups respectively achieved an EASI75 score, compared to just 12% of those receiving placebo.

The therapy also met its secondary endpoints of reduced skin inflammation and reduced itch severity, while its safety profile was found to be in line with previous data.

“Atopic dermatitis is chronic skin condition which affects approximately 1-3% of adults worldwide. We appreciate the distressing impact this condition can have on a person’s quality of life and the need for additional treatment options," commented Dr Doron Sagman, Vice President of R&D and Medical Affairs at Eli Lilly. "We are pleased that baricitinib met the primary endpoint in the BREEZE-AD5 study, and we will continue to focus on patient-centred solutions."

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches